Chantale Bernatchez, Ph.D.
Department of SVP Discovery & Platforms, Therapeutics Discovery
Present Title & Affiliation
Primary Appointment
Associate Director, Cell Therapy Process Development, Department of Biologics Development, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
2004 | Laval University, Quebec, CAN, PHD, Immunology |
1998 | Laval University, Quebec, CAN, MSc, Immunology |
1995 | Universite du Quebec a Trois-Rivieres, Quebec, CAN, BS, Medical Biology |
Postgraduate Training
2007-2008 | Postdoctoral Fellow, Cancer Immunology, MD Anderson Cancer Center, Melanoma Oncology department, Houston, TX |
2005-2005 | Postdoctoral Fellow, Immunology, Laval University, Quebec |
Experience & Service
Academic Appointments
Associate Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2020
Associate Professor, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2020
Assistant Professor, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2019
Assistant Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Senior Research Scientist, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2013
Research Scientist, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2011
Post-Doctoral Fellow, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2008
Administrative Appointments/Responsibilities
Co-director, Translational Molecular Pathology – Immuno Profiling Lab, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2020
Other Appointments/Responsibilities
Research Scientist, Bio-Quant Inc, San Diego, CA, 2005 - 2006
Consultantships
Scientific Advisory Board member, Myst Therapeutics, California, 2019 - Present
Consultant, Lion Biotechnologies, Woodlands Hill, California, 2014 - 2015
Honors & Awards
2011 | Citation for Excellence in Laboratory Research, Division of Cancer Medicine, MDACC-Employee Recognition and Award Program |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, Curti BD, Tagliaferri MA, Zalevsky J, Hannah AL, Hoch U, Aung S, Fanton C, Rizwan A, Iacucci E, Liao Y, Bernatchez C, Hurwitz ME, Cho DC. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discov 10(8):1158-1173, 2020. e-Pub 2020. PMID: 32439653.
- Corsini EM, Wang Q, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Reuben A, Vasquez ME, Bernatchez C, Wang J, Cascone T, Zhang J, Heymach JV, Gibbons DL, Haymaker CL, Sepesi B. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer 146:303-309, 2020. e-Pub 2020. PMID: 32619781.
- Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C. Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8+ T cells to memory T cells. Cancer Immunol Res 8(6):794-805, 2020. e-Pub 2020. PMID: 32213626.
- Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Haymaker CL, Sepesi B. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer 8(1), 2020. PMID: 32350118.
- Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun 11(1):1839, 2020. e-Pub 2020. PMID: 32296058.
- Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. PMID: 32188704.
- Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
- Parisi G, Saco JD, Salazar FB, Tsoi J, Krystofinski P, Puig-Saus C, Zhang R, Zhou J, Cheung-Lau GC, Garcia AJ, Grasso CS, Tavaré R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu AM, Comin-Anduix B, Charych D, Ribas A. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat Commun 11(1):660, 2020. e-Pub 2020. PMID: 32005809.
- Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Forget MA, Kahn LMS, Pazdrak B, Karki B, Hailemichael Y, Singh M, Vianden C, Vennam S, Bharadwaj U, Tweardy DJ, Haymaker C, Bernatchez C, Huang S, Rajapakshe K, Coarfa C, Hurwitz ME, Sznol M, Hwu P, Hoch U, Addepalli M, Charych DH, Zalevsky J, Diab A, Overwijk WW. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun 11(1):661, 2020. e-Pub 2020. PMID: 32005826.
- Creasy CA, Forget MA, Singh G, Tapia C, Xu M, Stephen B, Sabir S, Meric-Bernstam F, Haymaker C, Bernatchez C, Naing A. Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors. Eur J Immunol 49(12):2245-2251, 2019. e-Pub 2019. PMID: 31532833.
- Sakellariou-Thompson D, Forget MA, Hinchcliff E, Celestino J, Hwu P, Jazaeri AA, Haymaker C, Bernatchez C. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunol Immunother 68(11):1747-1757, 2019. e-Pub 2019. PMID: 31602489.
- Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. Cancer Discov 9(6):711-721, 2019. e-Pub 2019. PMID: 30988166.
- Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31137625.
- Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L, Wang J, van der Burg SH, Melief CJ, Glisson B. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol 5(1):67-73, 2019. e-Pub 2018. PMID: 30267032.
- Forget MA, Haymaker C, Amaria RN, Bernatchez C. TIL therapy and anti-CTLA4: can they co-exist?. Oncotarget 10(1):1-2, 2019. e-Pub 2019. PMID: 30713594.
- Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A 116(5):1692-1697, 2019. e-Pub 2019. PMID: 30635425.
- Tavera RJ, Forget MA, Kim YU, Sakellariou-Thompson D, Creasy CA, Bhatta A, Fulbright OJ, Ramachandran R, Thorsen ST, Flores E, Wahl A, Gonzalez AM, Toth C, Wardell S, Mansaray R, Radvanyi LG, Gombos DS, Patel SP, Hwu P, Amaria RN, Bernatchez C, Haymaker C. Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. J Immunother 41(9):399-405, 2018. e-Pub 2018. PMID: 29757889.
- Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y. Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma. Cancer Discov 8(11):1366-1375, 2018. e-Pub 2018. PMID: 30209080.
- Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell 175(4):984-997.e24, 2018. PMID: 30388455.
- Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
- Zhang M, Fritsche J, Roszik J, Williams LJ, Peng X, Chiu Y, Tsou CC, Hoffgaard F, Goldfinger V, Schoor O, Talukder A, Forget MA, Haymaker C, Bernatchez C, Han L, Tsang YH, Kong K, Xu X, Scott KL, Singh-Jasuja H, Lizee G, Liang H, Weinschenk T, Mills GB, Hwu P. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat Commun 9(1):3919, 2018. e-Pub 2018. PMID: 30254248.
- McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, Forget MA, Haymaker C, Bernatchez C, Satani N, Muller F, Roszik J, Kalra A, Heffernan T, Sood A, Hu J, Amaria R, Davis RE, Hwu P. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. J Natl Cancer Inst 110(7):777-786, 2018. e-Pub 2017. PMID: 29267866.
- Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin Cancer Res 24(14):3366-3376, 2018. e-Pub 2018. PMID: 29496759.
- Hu J, Sun C, Bernatchez C, Xia X, Hwu P, Dotti G, Li S. T cell homing therapy for reducing regulatory T cells and preserving effector T cell function in large solid tumors. Clin Cancer Res 24(12):2920-2934, 2018. e-Pub 2018. PMID: 29391351.
- Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6(1):48, 2018. e-Pub 2018. PMID: 29871672.
- Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27(5):977-987.e4, 2018. e-Pub 2018. PMID: 29628419.
- Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283, 2018. e-Pub 2018. PMID: 29387478.
- Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE. Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol 2018, 2018. e-Pub 2018. PMID: 30094412.
- Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C. 4-1BB agonist focuses CD8(+) tumor-infiltrating T-cell growth into a distinct repertoire capable of tumor recognition in pancreatic cancer. Clin Cancer Res 23(23):7263-7275, 2017. e-Pub 2017. PMID: 28947567.
- Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov 7(10):1088-1097, 2017. e-Pub 2017. PMID: 28733428.
- Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C. Multifaceted role of BTLA in the control of CD8+ T cell fate after antigen encounter. Clin Cancer Res 23(20):6151-6164, 2017. e-Pub 2017. PMID: 28754817.
- Parra ER, Uraoka N, Jiang M, Cook P, Gibbons D, Forget MA, Bernatchez C, Haymaker C, Wistuba II, Rodriguez-Canales J. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci Rep 7(1):13380, 2017. e-Pub 2017. PMID: 29042640.
- Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Lizée G, Yee C. SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. Cancer Immunol Res 5(8):618-629, 2017. e-Pub 2017. PMID: 28630054.
- Haymaker C, Yang Y, Wang J, Zou Q, Sahoo A, Alekseev A, Singh D, Ritthipichai K, Hailemichael Y, Hoang ON, Qin H, Schluns KS, Wang T, Overwijk WW, Sun SC, Bernatchez C, Kwak LW, Neelapu SS, Nurieva R. Absence of Grail promotes CD8(+) T cell anti-tumour activity. Nat Commun 8(1):239, 2017. e-Pub 2017. PMID: 28798332.
- Harao M, Forget MA, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM. 4-1BB-enhanced expansion of CD8+ TIL from triple-negative breast cancer unveils mutation-specific CD8+ T cells. Cancer Immunol Res 5(6):439-445, 2017. e-Pub 2017. PMID: 28473315.
- Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, Hwu P, Li S. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8(+) T Cells and Histone Acetyltransferases. Cancer Immunol Res 5(4):300-311, 2017. e-Pub 2017. PMID: 28223282.
- Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res 5(4):319-329, 2017. e-Pub 2017. PMID: 28254787.
- Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunol Res 5(2):100-105, 2017. e-Pub 2017. PMID: 28062513.
- Uemura M, Fa'ak F, Haymaker C, McQuail N, Sirmans E, Hudgens CW, Barbara L, Bernatchez C, Curry JL, Hwu P, Tetzlaff MT, Diab A. Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer 5:7, 2017. e-Pub 2017. PMID: 28116090.
- Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
- Forget MA, Tavera RJ, Haymaker C, Ramachandran R, Malu S, Zhang M, Wardell S, Fulbright OJ, Toth CL, Gonzalez AM, Thorsen ST, Flores E, Wahl A, Peng W, Amaria RN, Hwu P, Bernatchez C. A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes. Front Immunol 8:908, 2017. e-Pub 2017. PMID: 28824634.
- Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology 6(6):e1321187, 2017. e-Pub 2017. PMID: 28680759.
- Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167(2):397-404.e9, 2016. e-Pub 2016. PMID: 27667683.
- Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 14(1):168, 2016. e-Pub 2016. PMID: 27776519.
- Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol 9(1):81, 2016. e-Pub 2016. PMID: 27595932.
- Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2015. PMID: 26645196.
- Forget MA, Haymaker C, Dennison JB, Toth C, Maiti S, Fulbright OJ, Cooper LJ, Hwu P, Radvanyi LG, Bernatchez C. The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity. Oncoimmunology 5(2):e1057386, 2016. e-Pub 2015. PMID: 27057427.
- Im JS, Herrmann AC, Bernatchez C, Haymaker C, Molldrem JJ, Hong WK, Perez-Soler R. Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. PLoS One 11(7):e0160004, 2016. e-Pub 2016. PMID: 27467256.
- Uemura M, Fa'ak F, Haymaker C, McQuail N, Sirmans E, Hudgens CW, Barbara L, Bernatchez C, Curry JL, Hwu P, Tetzlaff MT, Diab A. A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer 4:55, 2016. e-Pub 2016. PMID: 27660709.
- Glitza IC, Haymaker C, Bernatchez C, Vence L, Rohlfs M, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Patel SP, Woodman SE, Hwu WJ, Radvanyi LG, Davies MA, Papadopoulos NE, Hwu P. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: A case report. Cancer Immunol Res 3(11):1201-6, 2015. e-Pub 2015. PMID: 26216417.
- Haymaker CL, Wu RC, Ritthipichai K, Bernatchez C, Forget MA, Chen JQ, Liu H, Wang E, Marincola F, Hwu P, Radvanyi LG. BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. Oncoimmunology 4(8):e1014246, 2015. e-Pub 2015. PMID: 26405566.
- Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, Liu S, Whittington M, Deng W, Li F, Bernatchez C, Radvanyi LG, Davies MA, Hwu P, Lizée G. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res 3(6):602-9, 2015. e-Pub 2015. PMID: 25795007.
- Forget MA, Malu S, Liu H, Toth C, Maiti S, Kale C, Haymaker C, Bernatchez C, Huls H, Wang E, Marincola FM, Hwu P, Cooper LJ, Radvanyi LG. Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma. J Immunother 37(9):448-460, 2014. PMID: 25304728.
- Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol 189(11):5476-84, 2012. e-Pub 2012. PMID: 23105141.
- Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 2012. e-Pub 2012. PMID: 23032743.
- Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18(19):5329-40, 2012. e-Pub 2012. PMID: 22850568.
- Zhang M, Maiti S, Bernatchez C, Huls H, Rabinovich B, Champlin RE, Vence LM, Hwu P, Radvanyi L, Cooper LJ. A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy. Clin Cancer Res 18(17):4733-42, 2012. e-Pub 2012. PMID: 22761473.
- Haymaker C, Wu R, Bernatchez C, Radvanyi L. PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint. Oncoimmunology 1(5):735-738, 2012. PMID: 22934265.
- Bernatchez C, Radvanyi LG, Hwu P. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol 39(2):215-26, 2012. PMID: 22484193.
- Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, Wardell S, Bastian BC, Woodman SE. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res 25(2):182-7, 2012. e-Pub 2012. PMID: 22236444.
- Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 18(2):160-75, 2012. PMID: 22453018.
- Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 34(3):236-50, 2011. PMID: 21389874.
- Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, Fernandez-Vina M, Cano P, Cooper L, Abbruzzese J, Hwu P, Chang DZ, Radvanyi LG. Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine 29(16):3021-30, 2011. e-Pub 2011. PMID: 21320548.
- Boilard E, Bourgoin SG, Bernatchez C, Surette ME. Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood 102(8):2901-9, 2003. e-Pub 2003. PMID: 12829607.
- Boilard E, Bourgoin SG, Bernatchez C, Poubelle PE, Surette ME. Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans. FASEB J 17(9):1068-80, 2003. PMID: 12773489.
- Surette ME, Fonteh AN, Bernatchez C, Chilton FH. Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells. Carcinogenesis 20:757-763, 1999.
- Leblanc E, Papadopoulou B, Bernatchez C, Quellette M. Residues involved in co-factor and substrate binding of the short-chain dehydrogenase/reductase PTR1 producing methotrexate resistance in Leishmania. Eur J Biochem 251:768-774, 1998.
- Bernatchez C, Al-Daccak R, Mayer PE, Mehindate K, Rink L, Mecheri S, Mourad W. Functional analysis of Mycoplasma arthritidis-derived mitogen interactions with class II molecules. Infect Immun 65(6):2000-5, 1997. PMID: 9169724.
Invited Articles
- Schalck A, Bernatchez C, Navin N. Resident Breast T Cells: The Troops Are Already There. Trends Mol Med 24(10):821-822, 2018. e-Pub 2018. PMID: 30077643.
- Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the Development of Cancer Immunotherapies. Trends Immunol 34(2):90-8, 2013. e-Pub 2012. PMID: 23031830.
- Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi L. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 18:160-175, 2012.
- Bernatchez C, Radvanyi L, Hwu P. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol 39:215-226, 2012.
Abstracts
- Haymaker, Cara; Chen, Jie Qing; Bernacthez, Chantale; Kale, Charuta; Torres-Cabala, Carlos; Radvanyi, Laszlo. Usurpation of a lymphocyte costimulatory molecule as a novel Melanoma cell survival pathway. American Association of Immunologists, Bethesda, MD 190, 2013.
- Haymaker, Cara; Wu, Richard; Bernatchez, Chantale; Hwu, Patrick; Radvanyi, Laszlo. BTLA: new biomarker for a highly proliferative CD8+TIL subset associated with Melanoma regression during adoptive cell therapy. American Association of Immunologists, Bethesda, MD 190, 2013.
- Radvanyi L, R., C. Bernatchez, M. Zhang, P. Miller, M. Glass, R.Bassett, J. D. McMannis, E. Shpall, V. Prieto, N. Papadopoulos, and P. Hwu. Adoptive T-cell Therapy for Metastatic Melanoma: The MD Anderson Experience. International Society for Biological Therapy of Cancer (iSBTc) 25th Annual Meeting, Washington D.C. and NIH campus, Bethesda, MD,, 2010.
- Bernatchez, C., Y. Li, C.G. Loannides, M. Fernandez-Vina, P. Cano, D.Z. Chang and L. Radvanyi. New epitopes to improve peptide vaccination against the tumor-associated antigen Survivin., Experimental Biology 2008, San Diego, CA,, 2008.
- Bernatchez, C., S.G. Bourgoin et M.E. Surette. Patron d'activation des membres de la famille RSK (ribosomal S6 kinases) lors d'une stimulation du recepteur des cellules T (TCR), 43rd annual reunion of Club de Recherches Cliniques du Quebec, Mont Ste-Anne (Quebec, Canada),, 2001.
- Bernatchez, C., S. G. Bourgoin and M.E. Surette. Pattern of activation of human of Rsk family members upon T cell receptor stimulation, Experimental Biology 2001, Orlando, Florida,, 2001.
- Surette, M.E., C. Bernatchez and P. Borgeat. Autocrine activation of human PMN by LTB4 in the synthesis of 5-LO products from exogenous arachidonic acid: inhibition by adenosine A2 receptor agonists, Experimental Biology'99, Washington, D.C.,, 1999.
- Bernatchez C., P. Borgeat and M.E. Surette. L'acide arachidonique exogene induit une forte synthese de leucotrienes par le neutrophile humain, ACFAS meeting, Quebec, Canada,, 1998.
Book Chapters
- Bernatchez C, Cooper ZA, Wargo JA, Hwu P, Lizée G. Novel Treatments in Development for Melanoma. In: Cancer Treat Res, 371-416, 2016.
Grant & Contract Support
Title: | Functional Attributes of a CD8+BTLA+T cell subset in Adoptive T Cell Therapy |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Interactive program to identify predictive biomarkers in TIL therapy |
Funding Source: | AMRF |
Role: | Collaborator |
Title: | Phase II study of MK-3475 in conjunction with lymphodepletion, TIL and high or low dose IL-2 in patients with metastatic melanoma |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | Biomarkers and Resistance Mechanisms in Melanoma T-Cell Therapy |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Melanoma CD8+ TIL functionality: BTLA and impact of checkpoint blockade therapy |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Identifying Rational Combinations of Immune and Targeted Therapies |
Funding Source: | Novartis |
Role: | Collaborator |
Title: | P4: Adoptive Cell Therapy Using Expanded Melanoma T Cells Programmed Ex Vivo for Improved Efficacy In Vivo |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-Investigator |
Title: | Elucidating the role of tumor metabolism in response to immunotherapy |
Funding Source: | Dr. Miriam &Sheldon G. Adelson Medical Research Foundation |
Role: | Collaborator |
Title: | A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies |
Funding Source: | Nektar Therapeutics |
Role: | Collaborator |
Title: | Melanoma Moonshot |
Funding Source: | Philanthropy - Moonshot funding |
Role: | Co-Investigator |
Title: | Evaluation of TIL in HPV+ cancer |
Funding Source: | Philanthropy-MDACC moonshot funding |
Role: | Co-Investigator |
Title: | Evaluation of TIL in NSCLC |
Funding Source: | Philanthropy - MDACC moonshot funding |
Role: | Co-Investigator |
Title: | Evaluation of TIL in pancreatic ductal adenocarcinoma |
Funding Source: | Philanthropy - MDACC moonshot funding |
Role: | Co-Investigator |
Title: | UTMDACC SPORE in Melanoma – Project 2 Molecular and Immunologic Mechanisms of Response to TIL and anti PD-1 Antibody in Metastatic Melanoma |
Funding Source: | NIH/NCI |
Role: | Co-Program Leader |
Title: | Streamlining Autologous TIL Manufacturing for Multi-Center Trials |
Funding Source: | NIH/NCI |
Role: | Project Leader |
Title: | A Phase I/II Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma |
Funding Source: | Idera Pharmaceuticals |
Role: | Collaborator |
Title: | Translational Cancer Immune Monitoring and Analysis Center (TCIMAC) |
Funding Source: | NIH/NCI |
Role: | Co-Principal Investigator |
Title: | A Preclinical Investigation of Tumor-infiltrating Lymphocytes and their Immunologic Characteristics in Solid Tumors |
Funding Source: | Iovance Biotherapeutics |
Role: | Co-Principal Investigator |
Title: | Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) across Multiple Tumor Types |
Funding Source: | Iovance Biotherapeutics |
Role: | Co-Principal Investigator |
Title: | Clinical study to assess efficacy and safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types |
Funding Source: | Iovance Biotherapeutics |
Role: | Co-Principal Investigator |
Title: | Adoptive transfer of TGF-ß resistant TIL to defeat immunosuppressive PDAC |
Funding Source: | SU2C |
Role: | Co-Principal Investigator |
Title: | Helios CyTOF System: Mass Cytometer Shared Resource forImmunomonitoring of Clinical Trials |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Characterizing Cancer Genome Instability and Translational Impact Using New Sequencing Technologies |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
Title: | Evaluation of TIL in colorectal cancer |
Funding Source: | Philanthropy - MDACC moonshot funding |
Role: | Co-Investigator |
Title: | Therapeutic Potential of T Follicular Helper Cells for Melanoma Treatment |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-Investigator |
Title: | Optimizing Precision Therapies in Immuno-oncology Core (OPTIC) |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-Investigator |
Title: | Unconventional Tumor Antigen Discovery |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | The University of Texas MD Anderson Cancer Center SPORE in Melanoma - Parent Grant |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | The University of Texas MD Anderson Cancer Center SPORE in Gastrointestinal Cancer - Project 1: Personalized Adjuvant Immunotherapy for High-Risk Colorectal Cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | MD Anderson Cancer Center SPORE in Gastrointestinal Cancer (Project 1) |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Modulating the anti-tumor/bystander T cell balance for the treatment of non-small cell lung cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Elucidating the transcriptomic features of TGF- β resistant TIL associated with clonal expansion and persistence after adoptive transfer using scRNAseq combined with scTCRseq to improve immunotherapy for solid tumors |
Funding Source: | UTMDACC Melanoma SPORE DRP |
Role: | Principal Investigator-MDACC |
Title: | The Interplay of Tumor Metabolic and Oncogenic Pathways in Immune Resistance |
Funding Source: | University of Houston |
Role: | Subcontract |